Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat in compensated alcohol-related cirrhosis with clinically significant portal hypertension
jRCT2031210586Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of avenciguat in Portal Hypertension (PH) and Cirrhosis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in hepatic venous pressure gradient from baseline after 24 weeks of treatment. Started Feb 2022; status: completed.
02
Drugs
avenciguat
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on jRCT2031210586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210586.